Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

TAKEDA PHARMACEUTICAL COMPANY LIMITED

(4502)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Takeda Pharmaceutical : Obtains Regulatory Approval to Manufacture, Market Alofisel in Japan

09/27/2021 | 04:53am EDT


© MT Newswires 2021
All news about TAKEDA PHARMACEUTICAL COMPANY LIMITED
10/21TAKEDA PHARMACEUTICAL : to Hold Second Quarter FY2021 Earnings Conference Calls
PU
10/20NOVAVAX : Dismisses Media Report on COVID-19 Vaccine Quality, Production Delays; Shares Do..
MT
10/20NOVAVAX : Refutes Media Report on its COVID-19 Vaccine Quality, Production Delays
MT
10/18WAVE LIFE SCIENCES : Takeda Pharmaceutical Partially Amend Central Nervous System Collabor..
MT
10/18CALITHERA BIOSCIENCES : Buys Two Clinical-Stage Assets from Takeda to Boost Oncology Pipel..
MT
10/18Calithera Expands Oncology Pipeline with Acquisition of Two Clinical-Stage Assets from ..
CI
10/18Calithera Agrees to Acquire 2 Clinical-Stage Assets from Takeda Pharma
DJ
10/14TAKEDA PHARMACEUTICAL : Working With Immusoft to Develop B-Cell Therapies for Rare Neurome..
MT
10/13TR1 : Notification of Major Shareholding
DJ
10/13TAKEDA PHARMACEUTICAL : BioLife Plasma Services Announces Expansion of Plasma Donation Cen..
BU
More news
Analyst Recommendations on TAKEDA PHARMACEUTICAL COMPANY LIMITED
More recommendations
Financials
Sales 2022 3 389 B 29 707 M 29 707 M
Net income 2022 249 B 2 185 M 2 185 M
Net Debt 2022 3 258 B 28 559 M 28 559 M
P/E ratio 2022 20,2x
Yield 2022 5,61%
Capitalization 5 043 B 44 337 M 44 213 M
EV / Sales 2022 2,45x
EV / Sales 2023 2,31x
Nbr of Employees 47 099
Free-Float 99,3%
Chart TAKEDA PHARMACEUTICAL COMPANY LIMITED
Duration : Period :
Takeda Pharmaceutical Company Limited Technical Analysis Chart | 4502 | JP3463000004 | MarketScreener
Technical analysis trends TAKEDA PHARMACEUTICAL COMPANY LIMITED
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 14
Last Close Price 3 207,00 JPY
Average target price 4 487,14 JPY
Spread / Average Target 39,9%
EPS Revisions
Managers and Directors
Christophe Weber President, CEO & Representative Director
Constantine Saroukos Chief Financial Officer & Director
Andrew S. Plump Director, Research & Development President
Michael E. Mendelsohn Chief Medical & Scientific Officer
Norimasa Takeda Chief Accounting Officer & Corporate Controller
Sector and Competitors
1st jan.Capi. (M$)
TAKEDA PHARMACEUTICAL COMPANY LIMITED-14.59%44 688
JOHNSON & JOHNSON3.83%431 148
ROCHE HOLDING AG13.98%333 101
PFIZER, INC.16.27%239 966
NOVO NORDISK A/S56.26%238 738
ELI LILLY AND COMPANY42.84%220 952